Hisato Shima

Dr. Hisato Shima

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
KKKoichi Kikuchi
Koichi Kikuchi
DSDaisuke Saigusa
Daisuke Saigusa
YKYoshitomi Kanemitsu
Yoshitomi Kanemitsu
YMYotaro Matsumoto
Yotaro Matsumoto
PTPaxton Thanai
Paxton Thanai
TATakaaki Abe
Takaaki Abe
Diabetic kidney disease is a major cause of renal failure that urgently necessitates a breakthrough in disease management. Here we show using untargeted metabolomics that levels of phenyl sulfate, a gut microbiota-derived metabolite, increase with the progression of diabetes in rats overexpressing human uremic toxin transporter SLCO4C1 in the kidney, and are decreased in rats with limited proteinuria. In experimental models of diabetes, phenyl sulfate administration induces albuminuria and podocyte damage. In a diabetic patient cohort, phenyl sulfate levels significantly correlate with basal and predicted 2-year progression of albuminuria in patients with microalbuminuria. Inhibition of tyrosine phenol-lyase, a bacterial enzyme responsible for the synthesis of phenol from dietary tyrosine before it is metabolized into phenyl sulfate in the liver, reduces albuminuria in diabetic mice. Together, our results suggest that phenyl sulfate contributes to albuminuria and could be used as a disease marker and future therapeutic target in diabetic kidney disease.

8 June 2018 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
HSHisato Shima
Hisato Shima
KMKeiko Miya
Keiko Miya
KOKazuyoshi Okada
Kazuyoshi Okada
JMJun Minakuchi
Jun Minakuchi
SKShu Kawashima
Shu Kawashima
Sucroferric oxyhydroxide, a novel iron-based phosphate-binder, has been shown to have beneficial effects in lowering serum phosphorus levels and improving renal anemia in clinical studies. Although an effect of this agent on fibroblast growth factor 23 (FGF23) has been reported in an animal study, there is little clinical data supporting this finding. This study aimed to evaluate the effect on chronic kidney disease-mineral and bone disorder, FGF23, renal anemia, iron-related parameters, adverse events of sucroferric oxyhydroxide in hemodialysis patients. Hemodialysis patients, receiving existing hyperphosphatemia drugs with insufficient benefit, were administered sucroferric oxyhydroxide with/without calcium carbonate for 16 weeks. Serum phosphorus level declined rapidly in Week 8 (p < 0.0001) and this decrease persisted until Week 16 (p < 0.0001). FGF23 decreased (p = 0.0412, Week 16), and hemoglobin increased (p < 0.0001, Week 16). Cumulative dose of erythropoiesis-stimulating agents (p = 0.0122, Week 16), and intravenous iron (p = 0.0233, Week 12) decreased. All adverse reactions were mild, and diarrhea was the most frequently observed adverse reaction (16.7%). Therefore, hyperphosphatemia treatment with sucroferric oxyhydroxide may safely improve serum phosphorus level, renal anemia, FGF23, and other factors that affect the prognosis of hemodialysis patients.

2 April 2018 in CEN Case Reports
Verified
Journal Article
Closed access
PDF file
HSHisato Shima
Hisato Shima
SMShogo Mizoguchi
Shogo Mizoguchi
YMYuji Morine
Yuji Morine
MTManabu Tashiro
Manabu Tashiro
KOKazuyoshi Okada
Kazuyoshi Okada
SKShu Kawashima
Shu Kawashima

24 March 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MTManabu Tashiro
Manabu Tashiro
KOKazuyoshi Okada
Kazuyoshi Okada
YTYusaku Tanaka
Yusaku Tanaka
HMHiroyuki Michiwaki
Hiroyuki Michiwaki
HSHisato Shima
Hisato Shima
JMJun Minakuchi
Jun Minakuchi
Background: Online hemodiafiltration (OHDF) has a lower mortality rate than hemodialysis (HD). We aimed to investigate the impact of the albumin leakage on the mortality of patients receiving HD or OHDF. Methods: In this single-center study, consecutive patients receiving renal replacement therapy between January and April 2018 were retrospectively registered. Using (1:1) propensity score matching, 3-year all-cause mortality was compared between patients receiving HD and OHDF, and the impact of albumin leakage on the mortality rate in both groups was investigated. Results: Of the 460 patients, 137 patients receiving HD were matched with an equal number of patients receiving OHDF. OHDF was associated with higher albumin leakage (p < 0.001) and a lower mortality than HD (log-rank test, p < 0.001). Albumin leakage was associated with mortality in patients receiving HD (per 1 g increase, hazard ratio (HR): 0.495, 95% confidence interval (CI): 0.275–0.888) and patients receiving OHDF (per 1 g increase, HR: 0.734, 95% CI: 0.588–0.915). Patients receiving HD, with the highest albumin leakage tertile (>3 g), had a similar mortality rate to patients receiving OHDF, with similar albumin leakage. Conclusions: The negative relationship between albumin leakage and mortality suggests the benefit of removing middle- to -large-molecular-weight substances to improve survival.

1 August 2020 in CEN Case Reports
Verified
Journal Article
Closed access
PDF file
YNYoko Nishiuchi
Yoko Nishiuchi
HSHisato Shima
Hisato Shima
YFYoshio Fukata
Yoshio Fukata
TTTomohiro Tao
Tomohiro Tao
TOTakuya Okamoto
Takuya Okamoto
JMJun Minakuchi
Jun Minakuchi

5 March 2018 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
HSHisato Shima
Hisato Shima
MTManabu Tashiro
Manabu Tashiro
SYSatoshi Yamada
Satoshi Yamada
MMMotokazu Matsuura
Motokazu Matsuura
KOKazuyoshi Okada
Kazuyoshi Okada
SKShu Kawashima
Shu Kawashima
Cilostazol is an antiplatelet drug that is widely prescribed for the prevention of secondary stroke. Adverse reactions to cilostazol include headaches, palpitations, and diarrhea. Little is known about the nephrotoxicity of cilostazol, such as acute kidney injury. We report a biopsy-proven case of diffuse tubulointerstitial nephritis induced by cilostazol. A 69-year-old woman prescribed cilostazol was hospitalized for acute kidney injury. On admission, her renal function deteriorated, with an increased serum creatinine level. Urinalysis showed hematuria, proteinuria, and hyper-beta2-microglobulinuria. A renal biopsy revealed diffuse tubulointerstitial nephritis associated with IgA nephropathy, and gallium-67 scintigraphy showed uptake in the bilateral kidneys. A drug lymphocyte stimulation test for cilostazol was positive, and the patient was diagnosed with cilostazol-induced acute tubulointerstitial nephritis. Despite discontinuation of cilostazol, her renal function rapidly worsened and steroid pulse therapy was initiated, followed by oral high-dose glucocorticoid therapy. After steroid treatment, her serum creatinine level normalized in parallel with urine beta2-microglobulin. Cilostazol can induce acute tubulointerstitial nephritis.